A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

The key inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Male/Female Chinese adult participant of an allogeneic Hematopoietic Stem Cell Transplant (HSCT). * Has documented positive Cytomegalovirus (CMV) serostatus (CMV immunoglobulin G \[IgG\] seropositive) for recipient (R+) at the time of screening. * Is receiving a first allogeneic HSCT. * Is within 28 days post-HSCT at the time of randomization. * Female participant is not a Woman of Child Bearing Potential (WOCBP) or is a WOBCP who agrees to use acceptable contraception during the treatment period and for ≥28 days after the last dose of study drug. Exclusion Criteria: * Received a previous allogeneic HSCT. * Has a history of CMV end-organ disease within 6 months prior to randomization. * Has evidence of CMV viremia at any time from HSCT procedure until the time of randomization. * Has severe hepatic insufficiency. * Is a) on renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) OR b) has end stage renal impairment with a creatinine clearance \<=10 mL/min within 5 days prior to randomization. * Has both moderate hepatic insufficiency AND moderate to severe renal insufficiency. * Has an uncontrolled infection on the day of randomization. * Has rapidly progressing disease that requires mechanical ventilation or is hemodynamically unstable. * Has a documented positive result for a human immunodeficiency virus antibody (HIV-Ab) test at any time prior to ran…